Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.21.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
Current assets:    
Cash and cash equivalents $ 199,091 $ 146,625
Short-term available-for-sale investments 32,463 124,268
Accounts receivable, less allowance for doubtful accounts of $1,229 and $775, respectively 145,385 122,534
Inventories 116,748 103,152
Other current assets 16,919 24,341
Total current assets 510,606 520,920
Property and equipment, net 207,907 176,829
Right of use asset 73,834 [1] 71,465
Goodwill 843,067 728,308
Intangible assets, net 615,968 516,545
Other assets 11,575 13,522
Total assets 2,262,957 2,027,589
Current liabilities:    
Trade accounts payable 29,384 23,090
Salaries, wages and related accruals 51,294 31,087
Accrued expenses 15,282 9,093
Contract liabilities 18,995 13,049
Income taxes payable 5,336 2,376
Operating lease liabilities - current 11,602 [1] 9,535
Contingent consideration payable 4,000 5,938
Current portion of long-term debt obligations 12,500 12,500
Other current liabilities 3,891 0
Total current liabilities 152,284 106,668
Deferred income taxes 93,125 101,090
Long-term debt obligations 328,827 344,243
Long-term contingent consideration payable 25,400 199
Operating lease liabilities 67,625 [1] 67,248
Other long-term liabilities 24,462 26,949
Bio-Techne's shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 a share; authorized 100,000,000 shares; issued and outstanding 38,955,484 and 38,453,046 shares, respectively 390 385
Additional paid-in capital 534,411 420,536
Retained earnings 1,085,461 1,057,470
Accumulated other comprehensive loss (57,291) (97,199)
Total Bio-Techne shareholders' equity 1,562,971 1,381,192
Noncontrolling interest 8,263 0
Total shareholders' equity 1,571,234 1,381,192
Total liabilities and shareholders’ equity $ 2,262,957 $ 2,027,589
[1] The right of use asset, current operating lease liabilities, and noncurrent lease liabilities on the Consolidated Balance Sheet exclude a definitive agreement entered into by the Company in June 2021 for a 25,000 square foot facility in Dublin, Ireland for the next 25 years with annual rental impact of $0.3 million. The lease will commence during fiscal 2022 after construction is completed by the landlord. As the lease has not commenced as of June 30, 2021, the related asset and liability were not recorded.